Trial · NCT03992196
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Rotigotine Final Dose 2 mg/24 h | 100 | percentage of participants | ||
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Rotigotine Final Dose 3 mg/24 h | 85.7 | percentage of participants | ||
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal of Study Medication | Rotigotine Final Dose 2 mg/24 h | 0 | percentage of participants | ||
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal of Study Medication | Rotigotine Final Dose 3 mg/24 h | 0 | percentage of participants | ||
| Changes From Baseline in International Restless Legs Rating Scale (IRLS) Sum Score at Visit 9 | Rotigotine Final Dose 2 mg/24 h | NA | Standard Deviation NA | score on a scale | |
| Changes From Baseline in International Restless Legs Rating Scale (IRLS) Sum Score at Visit 9 | Rotigotine Final Dose 3 mg/24 h | NA | Standard Deviation NA | score on a scale | |
| Changes From Baseline in Clinical Global Impressions (CGI) Item 1 at Visit 9 | Rotigotine Final Dose 2 mg/24 h | NA | Standard Deviation NA | score on a scale | |
| Changes From Baseline in Clinical Global Impressions (CGI) Item 1 at Visit 9 | Rotigotine Final Dose 3 mg/24 h | NA | Standard Deviation NA | score on a scale | |
| Changes From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9 | Rotigotine Final Dose 2 mg/24 h | Satisfaction with sleep | NA | Standard Deviation NA | score on a scale |
| Changes From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9 | Rotigotine Final Dose 3 mg/24 h | Satisfaction with sleep | NA | Standard Deviation NA | score on a scale |
| Changes From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9 | Rotigotine Final Dose 2 mg/24 h | Severity: RLS symptoms at falling asleep | NA | Standard Deviation NA | score on a scale |
| Changes From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9 | Rotigotine Final Dose 3 mg/24 h | Severity: RLS symptoms at falling asleep | NA | Standard Deviation NA | score on a scale |
| Changes From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9 | Rotigotine Final Dose 2 mg/24 h | Severity: RLS symptoms during the night | NA | Standard Deviation NA | score on a scale |
| Changes From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9 | Rotigotine Final Dose 3 mg/24 h | Severity: RLS symptoms during the night | NA | Standard Deviation NA | score on a scale |
| Changes From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9 | Rotigotine Final Dose 2 mg/24 h | Severity: RLS symptoms during the day - at rest | NA | Standard Deviation NA | score on a scale |
| Changes From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9 | Rotigotine Final Dose 3 mg/24 h | Severity: RLS symptoms during the day - at rest | NA | Standard Deviation NA | score on a scale |
| Changes From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9 | Rotigotine Final Dose 2 mg/24 h | Severity: RLS symptoms during the day-not at rest | NA | Standard Deviation NA | score on a scale |
| Changes From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9 | Rotigotine Final Dose 3 mg/24 h | Severity: RLS symptoms during the day-not at rest | NA | Standard Deviation NA | score on a scale |
| Changes From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9 | Rotigotine Final Dose 2 mg/24 h | How tired or sleepy during the day | NA | Standard Deviation NA | score on a scale |
| Changes From Baseline in Restless Legs-6 Rating Scales (RLS-6) at Visit 9 | Rotigotine Final Dose 3 mg/24 h | How tired or sleepy during the day | NA | Standard Deviation NA | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03992196/results